Biovian announces investment in manufacturing facility in Finland
Biopharmaceutical based contract development and manufacturing organisation (CDMO) Biovian OY has announced an investment of over €50m to expand its manufacturing facility based in Turku, Finland.
The facility is expected to cover 6,400sqm and will be home to cutting-edge equipment and technology aiming to support the development, manufacturing and testing of advanced therapy medicinal products (ATMP) therapies. It will also house dedicated class A to D cleanroom areas for bulk drug substances and final drug product manufacturing.
The expansion is expected to be completed by December 2024, with the facility intended to become fully operational by 2025.
Antti Nieminen, Biovian’s chief executive officer, commented: “The new manufacturing facility will not only strengthen Biovian’s position as a key player in the CDMO sector, but also contribute to the growth of the biopharmaceutical industry in Finland, and most of all provide vital therapies to patients suffering from today’s untreatable diseases. Biovian aims to facilitate swift drug development and delivery, reducing time-to-market for its customers, all while creating an enjoyable experience. The new manufacturing facility will increase viral vector capacity, but it will also increase our capacity and flexibility in microbial protein. When the new site is up and running, our existing capacity will be transformed to new microbial protein suites. Thus, both microbial and viral vector customers will benefit from this expansion.”
Astellas Pharma has announced that it is preparing to submit a planning application to build …
Virtual inspections must become a part of companies’ repertoires if they aim to maintain quality …